Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Respiratory complications of obesity: from early changes to respiratory failure

Neeraj M. Shah, Georgios Kaltsakas
Breathe 2023 19: 220263; DOI: 10.1183/20734735.0263-2022
Neeraj M. Shah
1Lane Fox Respiratory Service, St Thomas’ Hospital, Guy's and St Thomas’ NHS Foundation Trust, London, UK
2Lane Fox Clinical Respiratory Physiology Centre, Guy's and St Thomas’ NHS Foundation Trust, London, UK
3Centre for Human and Applied Physiological Sciences (CHAPS), King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: neeraj.shah@gstt.nhs.uk
Georgios Kaltsakas
1Lane Fox Respiratory Service, St Thomas’ Hospital, Guy's and St Thomas’ NHS Foundation Trust, London, UK
2Lane Fox Clinical Respiratory Physiology Centre, Guy's and St Thomas’ NHS Foundation Trust, London, UK
3Centre for Human and Applied Physiological Sciences (CHAPS), King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Obesity is a significant and increasingly common cause of respiratory compromise. It causes a decrease in static and dynamic pulmonary volumes. The expiratory reserve volume is one of the first to be affected. Obesity is associated with reduced airflow, increased airway hyperresponsiveness, and an increased risk of developing pulmonary hypertension, pulmonary embolism, respiratory tract infections, obstructive sleep apnoea and obesity hypoventilation syndrome. The physiological changes caused by obesity will eventually lead to hypoxic or hypercapnic respiratory failure. The pathophysiology of these changes includes a physical load of adipose tissue on the respiratory system and a systemic inflammatory state. Weight loss has clear, well-defined benefits in improving respiratory and airway physiology in obese individuals.

Abstract

Obesity has significant and wide-ranging effects on respiratory function, and is an important contributor to morbidity and mortality https://bit.ly/3k8bGmX

Educational aims

  • Provide an understanding of the physiological changes that obesity causes on the respiratory system.

  • Describe the mechanisms that explain why obesity is a risk factor for the development of various respiratory conditions.

  • Explain the association between obesity and obstructive sleep apnoea, obesity hypoventilation syndrome and respiratory failure.

  • Provide an overview of the benefits of weight loss on the respiratory system.

Introduction

The accumulation of adipose tissue above socially accepted norms has been recognised as a significant contributor to numerous chronic diseases since the classical age [1]. Despite this, being overweight has been considered a sign of wealth and wellbeing for much of human history [2]. Only in the past century have perceptions changed. Obesity was finally recognised as a disease state by the National Institutes of Health in 1998 [3]. While the association of increasing body mass index (BMI) with cardiovascular comorbidity and glucose dysfunction is recognised and has become embedded into clinical practice, obesity is also associated with a systemic inflammatory state, gastrointestinal disorders, malignancy, psychological and importantly, respiratory comorbidity [4]. The pathophysiology of these complications is less well known and understood and therefore deserves attention. Respiratory complications of obesity include airway disorders, impaired physiology, pulmonary vascular disease, respiratory tract infections and ultimately ventilatory failure (figure 1). This review uses a systematic approach to describe the pathophysiological processes that lead to these complications and the impact of potential treatments. Although the respiratory complications of obesity have been recognised in the literature throughout history, only in the past 30–40 years have these been actively considered and acted upon by clinicians and public health organisations [5].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Associations between the respiratory system and obesity, delineating where obesity is causative and where obesity is a risk factor.

Epidemiology

Obesity is classified into categories based on BMI, into moderate (BMI 30–35 kg·m−2), severe (BMI 35–40 kg·m−2) and morbid obesity (BMI >40 kg·m−2). In addition, a supranormal BMI of 25–30 kg·m−2 is considered as overweight. With increasing BMI, come increasing severity of complications, in both cardiovascular and respiratory function [4]. The pattern of obesity also has an impact on respiratory comorbidity. Individuals with an abdominal pattern are more likely to suffer from respiratory compromise than those with a peripheral pattern, due to the physical constraints central adipose tissue places on the diaphragm [6]. Global obesity prevalence has increased from 3.2% in 1975 to 10.8% in 2014 in men, and from 6.4% to 14.9% in women [7]. All classes of obesity are becoming more prevalent [8, 9]. It is therefore imperative that all clinicians are aware of the impact obesity can have on their patients’ respiratory physiology, as they are almost always going to be treating overweight individuals on a regular basis.

Pulmonary physiology

The impact of obesity on lung volumes stems primarily from its impact on thoracic compliance. Thoracic, or chest wall, compliance is attenuated in obese patients due to the physical limitation on chest wall expansion and diaphragm contraction that abdominal and chest wall adipose tissue places [10–12]. Lung compliance is also reduced in obesity mainly due to an increase in pulmonary blood flow [13], but also due to closure of the peripheral airways leading to a consequent chronic microatelectasis [14]. Additionally, reduction of functional residual capacity (FRC) may lead to increased alveolar surface tension further decreasing the lung compliance [8]. However, the contribution of reduced lung compliance appears to be less important than thoracic compliance [15].

The earliest and most commonly reported effect of obesity on static lung volumes is a reduction in expiratory reserve volume (ERV), usually with a conserved residual volume, which ultimately results in a reduction in FRC [16, 17]. Increasing severity of obesity is exponentially correlated with reducing ERV [16], and inversely proportional to other static lung volumes and capacities [16, 18]. A similar relationship is observed with end-expiratory lung volume [19]. Total lung capacity (TLC) tends to be normal, except in morbidly obese individuals where it can reduce by up to 20% [16], resulting in a restrictive defect. Therefore, if TLC is reduced in individuals with a BMI of up to 40 kg·m−2, an alternative or additional respiratory condition should be sought, as obesity alone is unlikely to be causing this degree of respiratory compromise [12]. The effects on static lung volumes are observed far more frequently in those with an abdominal pattern of obesity compared to those with a gynaecoid pattern, due to its impact on the diaphragm [6].

Vital capacity (VC), forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) tend to be mildly reduced in obese individuals, resulting in a normal or close to normal FEV1/FVC ratio [17, 18, 20]. Maximum expiratory flow 25–75% of FVC can be considerably reduced [18], reflecting small airway obstruction, and can be an early indicator of respiratory compromise in the context of obesity. Diffusion capacity tends to be normal or increased, reflecting the increase in pulmonary blood flow observed in obesity [13].

The sparse literature on the effects of obesity on respiratory muscle strength suggest that it remains mostly normal [20–23]. Posture appears to have an effect on respiratory muscle strength. In obese individuals, in the supine position maximal inspiratory pressure is significantly reduced compared with the upright position [24, 25]. Respiratory muscle endurance, evidenced by the maximum voluntary ventilation, is reduced with increasing BMI [26–28]. This is most likely because of reduced lung volumes and chest wall compliance and the subsequent increase in load on the respiratory system [29]. The direct impact of obesity on the structure of respiratory muscles remains unclear. Animal studies have suggested that the diaphragm thickens and has an increased concentration of type I and type IIb fibres [30, 31], which would increase its contractility. Animal studies have also demonstrated a fast-to-slow shift in myosin heavy chain phenotype [31, 32], which increases the endurance of the diaphragm. In summary, obesity contributes to a decrease in compliance and static lung volume, with mild impairment in FEV1/FVC and sparing of the respiratory musculature (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

The impact of obesity on parameters of respiratory physiology

Breathlessness on exertion is often described by overweight individuals without any respiratory compromise [33, 34]. The exact mechanisms to explain this are yet to be understood. In some early studies of overweight individuals with apparently normal respiratory physiology (i.e. normal spirometry), those reporting breathlessness on exertion were more likely to have a reduced maximum voluntary ventilation [35, 36]. Therefore, in some individuals, with unexplained breathlessness, further physiological investigations may reveal deficits. However, there is a cohort of overweight individuals in whom extensive cardiopulmonary investigation does not reveal any cause of breathlessness. Traditionally, breathlessness in these individuals was attributed to cardiopulmonary deconditioning. However, several studies have demonstrated normal aerobic capacity in these individuals. In individuals reporting exertional breathlessness, the sensation of the work of breathing is increased, compared with individuals without breathlessness, without any difference in the oxygen cost of breathing [37]. A potential explanation for this is a change in the “respiratory gate”, a subcortical mechanism designed to filter out insignificant respiratory stimuli. Obese individuals may have a lower threshold in this respiratory gate, allowing less important respiratory stimuli to stimulate the cortex, giving rise to the sensation of breathlessness [38]. This is a poorly investigated field and so managing breathlessness in obese individuals without any respiratory compromise can be challenging. In these individuals, psychophysiological factors contributing to the perception of breathlessness should be explored.

Airway limitation

Airway narrowing and a subsequent increase in resistance is a common feature in obese individuals, despite a preserved FEV1/FVC [39]. Body plethysmography demonstrated increasing airway resistance with increasing BMI [18]. Forced oscillation technique revealed almost double the airway resistance in obese individuals compared with controls [40, 41]. Furthermore, obese individuals displayed increased ΔXrs (difference between inspiratory and expiratory reactance), independent of the effect of low FRC, suggesting an additional mechanism causing airway flow limitation [42]. In patients with morbid obesity, negative expiratory pressure assessment revealed expiratory flow limitation in the supine position, when compared with age-matched controls [43]. The pathophysiology of airway narrowing in obese individuals can be classified into mechanical causes and hyperresponsiveness due to a pro-inflammatory state.

Lung volume is an important determinant of airway calibre [44]. In individuals with normal respiratory physiology, lung inflation causes a dose-dependent increase in airway calibre; the change in airway diameter is proportional to the cube root of the lung volume [45]. As obese individuals tend to breathe at lower FRC, the airway smooth muscles may be unloaded, allowing them to shorten excessively, causing airway narrowing. In addition, normal breathing imposes a tidal strain on airway smooth muscles, resulting in a bronchodilating effect. As obese individuals tend to breathe at a lower FRC, this bronchodilating effect is diminished, resulting in airway narrowing [46].

Obesity is associated with a systemic pro-inflammatory state (raised leukocytes, cytokines and chemokines) [47] and this has been demonstrated to be a contributor to a number of complications, including cardiovascular disease [48], glucose intolerance [49] and malignancy [50]. This pro-inflammatory state is also a potential cause of airway hyperresponsiveness in obese individuals. Airway eosinophils and neutrophils are not significantly increased in obese individuals; thus, this inflammatory state appears to be systemic [39]. Serum tumour necrosis factor (TNF)-α is increased in obese individuals. TNF-α receptors are found on airway smooth muscles, and in vitro, administration of TNF-α results in increased contractility of airway smooth muscles [51]. Leptin is a pro-inflammatory hormone produced by adipose cells that acts centrally to reduce hunger. Monocytes and macrophages respond to leptin with increased production of cytokines. As serum leptin levels are considerably increased in obese individuals, it is believed that airway hyperresponsiveness observed in obesity is at least partially caused by leptin [52]. Adiponectin is another hormone produced by adipose tissue, although serum adiponectin levels appear to be reduced in obese individuals [53]. Adiponectin inhibits TNF-α and so its reduction may have downstream effects on the contractility of airway smooth muscle [54]. Of note, bariatric surgery can result in a reduction in airway hyperresponsiveness and is associated with an increase in serum adiponectin and decrease in serum leptin [55]. In addition to those already discussed, there are probably many more molecular pathways contributing to airway hyperresponsiveness in obesity which will be elucidated with further work [56].

Asthma and COPD

Obesity has a considerable impact on both asthma and COPD; this is unsurprising as both conditions involve airway inflammation and changes to respiratory physiology.

The prevalence of asthma increases with BMI [57], as does its severity [58]. Asthma prevalence is 11% in obese individuals compared with only 7% in those with BMI <25 kg·m−2 [59]. Obese individuals are more likely to be hospitalised with an asthma exacerbation [60], and are less likely to respond to conventional inhaled corticosteroid therapy [61]. This is believed to be secondary to the pro-inflammatory state caused by obesity. Inhaled corticosteroids exert their effect on mitogen-activated protein kinase phosphatase-1 (MKP-1). The proinflammatory state in obesity appears to downregulate MKP-1, attenuating the impact of corticosteroids [62].

The interaction between obesity and COPD is less dose responsive. Although the prevalence of COPD does increase with increasing BMI [63], the severity of COPD adds complexity. In a study from the Netherlands, among patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 and 2 COPD the prevalence of obesity was 16–24%, whereas in patients with GOLD stage 4 COPD the prevalence of obesity was 6%. This was compared with a national prevalence of 10% [64, 65]. Studies of the mechanisms to explain the interaction between COPD and obesity are scarce, aside from the interactions in sleep disordered breathing. Both have an impact on pulmonary mechanics and ventilatory demand, and are likely to mutually amplify their effects. There is an “obesity paradox” phenomenon reported in COPD: increased BMI appears to be protective against all-cause mortality. The annual decline in FEV1 in men was lower in obese individuals with COPD than non-obese [66]. This is probably a reflection of the well-established causality between reduced BMI and all-cause mortality in COPD [67]. This paradox is not universal and is influenced by the heterogeneous phenotypes that characterise COPD. In patients with advanced COPD, obesity appears to be protective, when a low BMI is a significant contributor to all-cause mortality. By contrast, in patients with mild COPD, obesity appears to increase the risk of cardiovascular morbidity which in turn is a greater contributor to mortality than low BMI [68].

Pulmonary vascular disease

Obesity appears to be associated with an increased risk of developing pulmonary vascular disorders such as pulmonary hypertension and pulmonary embolism. Obesity has been demonstrated to be an independent risk factor for the development of all classes of pulmonary hypertension [69]. The literature suggests that obesity is associated with worse outcomes in patients with pulmonary arterial hypertension (PAH). A meta-analysis revealed that the response to treatment in patients with PAH was attenuated in those with increasing BMI [70] and health-related quality of life was worse in individuals with a raised BMI [71]. The effect of obesity on mortality in PAH remains unclear. Some studies report that obesity does not have any impact on mortality [72, 73], while others report a survival obesity paradox [69, 71, 74]. Mechanisms for an association between obesity and the development of pulmonary hypertension remain unclear [75], but have been postulated as being related to the presence of obstructive sleep apnoea (OSA), obesity hypoventilation syndrome (OHS) and the cardiomyopathy of obesity [76]. Murine data appear to suggest that pulmonary hypertension is associated with reduced serum adiponectin levels, which is a consequence of obesity, and that the administration of adiponectin is protective against the development of PAH [77]. Human studies have yet to be conducted, so the clear mechanism and potential therapeutic target for the development of pulmonary hypertension in obese individuals remains elusive.

Several large registry studies have demonstrated the strong association between obesity and the incidence of venous thromboembolism (VTE) [78–81]. Obesity is not only associated with an increased risk of primary VTE, but also recurrent VTE [82]. In addition, increasing BMI is proportional to increasing risk of VTE [83]. Although there is a strong relationship between incidence of VTE and BMI, its impact on outcome remains unclear. Studies have reported an obesity survival paradox in VTE [79, 84], but others have questioned whether these data reflect a true survival benefit or whether they reflect methodological challenges impacting the interpretation of their results [85, 86].

Respiratory tract infections and acute respiratory distress syndrome

Although obesity appears to cause a systemic pro-inflammatory state, until the coronavirus disease 2019 (COVID-19) pandemic, the association between obesity and respiratory tract infections remained unclear due to conflicting data. Mechanistic studies investigating the impact of obesity in animal models of influenza suggested that the presence of obesity results in an attenuated antiviral host response [87, 88]. This appeared to correlate with observational data from the H1N1 influenza epidemic reporting that obesity is a risk factor for the severity of disease [89–91] and admission to critical care and death [92]. This association between obesity and viral respiratory disease has been compellingly confirmed during the COVID-19 pandemic, with multiple reports demonstrating that obesity was a poor prognostic marker, with an increase in the development of COVID-19 pneumonitis [93], and increased risk of hospitalisation and death [94].

Several mechanisms to explain the association between obesity and COVID-19 have been explored. A well described mechanism is the impact of obesity on the angiotensin-converting enzyme 2 (ACE2) receptor. ACE2-R is an attachment site for the viral spike protein on the surface of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [95], allowing the virus to enter cells. The ACE2-R is found on lung epithelial cells as well as adipocytes, and is therefore upregulated in obese individuals [96]. Adipocytes act as a reservoir and replication site for SARS-CoV-2 [97], and so could result in prolonged viral shedding, as has been observed influenza [98]. Another mechanism is related to expression of interleukin-6 (IL-6). IL-6 is an independent risk factor for severity of COVID-19 [99]. Adipose tissue is a source of IL-6 secretion [100] and so it follows that obesity is likely to contribute to the impact of IL-6 on COVID-19 severity. Leptin is a pro-inflammatory molecule that stimulates production of pro-inflammatory cytokines such as TNF-α and IL-6. As already described, leptin is overexpressed in obesity and so may be an important contributor to the inflammatory response [101], and subsequent cytokine storm that is associated closely with morbidity and mortality [96, 102]. Several other molecular mechanisms remain under investigation, without definitive answers. To summarise, obesity results in a pro-inflammatory state through numerous mechanisms, which increases the degree of inflammatory response in COVID-19. In addition, obese individuals are more likely to suffer from other chronic conditions such as hypertension, cardiovascular disease, chronic kidney disease and type 2 diabetes mellitus which are all associated with increased morbidity and mortality in COVID-19 [103].

By contrast, the evidence of an association between obesity and bacterial pneumonia remains equivocal. While some studies have reported that obesity is associated with self-reported incidence of respiratory tract infection [104], and an increased risk of hospitalisation [105], many other studies have reported on the obesity survival paradox from bacterial pneumonia. A meta-analysis of 12 observational studies including 1.5 million patients [106], and subsequent studies [107, 108], have demonstrated that although obesity is associated with an increased risk of contracting a bacterial respiratory tract infection, it appears to be inversely proportional to mortality. No satisfactory mechanistic explanation has been elicited for this disparity in outcomes between viral and bacterial respiratory tract infections in obese individuals. While many theories have been speculated, none are yet supported by compelling evidence [109]. Obesity is an independent risk factor for the development of acute respiratory distress syndrome [110]. Despite this, obesity has been associated with an equivalent or better survival outcome compared with individuals with a normal BMI [111–113]. This is an example of the so-called obesity survival paradox, which states that somewhat counterintuitively, patients admitted to the intensive care unit are less likely to die if they have a raised BMI when compared with those with either a normal or low BMI.

Respiratory failure

Ultimately, the combination of these physiological changes can result in the development of ventilatory failure in obese individuals. The load–capacity–drive relationship is a useful framework to discuss the pathophysiology of alveolar hypoventilation and consequent hypercapnic respiratory failure in obesity [114]. Increased load on the respiratory system and a failure to adequately increase neural respiratory drive ultimately results in alveolar hypoventilation (figure 2), As discussed earlier, respiratory muscle capacity does not tend to be affected in obese individuals.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

The effect of pathophysiological changes of obesity on load–capacity–drive and their contribution to the development of hypoventilation. PEEP: positive end-expiratory pressure.

Load on the respiratory system is the combination of resistive load (increased resistance to airflow), elastic load (inversely proportional to compliance) and threshold load (intrinsic positive end-expiratory pressure (PEEPi)). As described earlier, airway resistance is increased in obese individuals, thus increasing resistive load. Both lung and chest wall compliance are reduced in obesity. Lung compliance due to breathing at lower lung volume which causes microatelectasis, and chest wall compliance due to the physical pressure of adipose tissue on the expansive ability of the rib cage [115]. Reduced pulmonary compliance results in an increase in elastic load. PEEPi is increased in obese individuals [23, 116], particularly in the supine position [43], demonstrating increased threshold load. This may be explained by expiratory flow limitation in the supine position, causing gas trapping at the end of expiration and thereby generating PEEPi [43].

Neural respiratory drive is the mechanism by which the medullary respiratory centre controls the rate and work of breathing in response to pH and arterial carbon dioxide tension. Obese individuals tend to exhibit increased neural drive, in order to increase minute ventilation and overcome the increased load on the respiratory system [20, 23, 43, 117]. This is often associated with an increased perception of breathlessness [114]. With increasing BMI, there is an increased risk of being unable to raise respiratory drive to compensate for the added load [118, 119]. Without this compensatory mechanism, increasing respiratory load will result in alveolar hypoventilation and consequent hypercapnic respiratory failure. Obese individuals who suffer from daytime hypercapnia in the absence of other causes of hypercapnia are considered to have OHS [5].

OSA

OSA is a relatively common condition associated with recurrent apnoeas during sleep caused by intermittent closure of the upper airway. Obesity has a very close relationship with OSA; 60–70% of OSA patients are obese [120, 121]. Further, an increase in BMI appears to increase the risk of developing OSA. A 10% weight gain results in a six-fold increase in the likelihood of developing OSA [122]. Obesity appears to contribute to OSA by two primary mechanisms:

1) the deposition of adipose tissue on the anterior neck results in a physical obstruction of an already floppy airway during sleep;

2) as described earlier, obese individuals breathe at reduced lung volumes, and this reduces airway calibre. Reduced airway calibre results in an increased likelihood of airway collapse during sleep [123].

In addition, poor sleep as a consequence of OSA may contribute to increasing BMI, which in turn worsens the degree of OSA. Poor sleep is associated with reduced serum leptin, which is an appetite suppressant [124]. Reducing serum leptin may increase appetite resulting in an increase in oral intake and therefore weight gain [125]. Finally, weight loss appears to improve the symptoms and severity of OSA [126, 127], further cementing the relationship between weight gain and the development of OSA.

OHS

Individuals with OHS are categorised into those with associated OSA (90%) and those without (10%) [128–130]. Lone OHS is caused by the inability to compensate for the increased load on the respiratory system, resulting in alveolar hypoventilation. In patients with OSA, intermittent ceased ventilation, continued metabolic production of carbon dioxide (CO2) and increased work of breathing against an occluded airway can result in hypercapnia. Ordinarily, this is compensated for by an increase in alveolar ventilation [131]. In patients with superimposed OHS, the time period between apnoeas tends to be shorter [130], resulting in inadequate CO2 clearance. This compounds the effects of the changes to the pulmonary mechanics already described, resulting in alveolar hypoventilation and hypercapnia. Hypercapnia during sleep effects an increase in bicarbonate to buffer the CO2. As this is a slow process, raised serum bicarbonate persists during wakefulness, blunting the ventilatory response to CO2 in subsequent sleep, making hypoventilation worse and exacerbating hypercapnia [132]. This will eventually lead to daytime hypercapnia.

Weight loss

The impact of weight loss, whether by controlled diet or bariatric surgery, on respiratory physiology in both eucapnic and hypercapnic individuals has been investigated extensively, but mostly in small observational studies. The data is convincing on the positive impact of weight loss on ERV [26, 29, 133–137], TLC [29, 133, 135, 138–140], FRC [29, 135, 138, 140, 141] and FVC [135, 138–140, 142–144]. A modest increase in respiratory muscle strength [29] has been reported, albeit from normal strength at baseline [141], with more convincing data to suggest an increase in respiratory muscle endurance [29, 138, 141, 145]. In eucapnic obese individuals, neural respiratory drive was reduced [146], while in hypercapnic obese individuals, neural drive was increased [145]. The positive impact of all of these physiological changes is illustrated by the clear reduction in hypercapnia observed after weight loss [147].

Summary

Obesity is a significant contributor to respiratory morbidity. Increasing BMI has deleterious effects on static and dynamic pulmonary volumes and causes airway flow limitation and increased airway hyperresponsiveness. Obesity increases the risk of pulmonary hypertension, pulmonary embolism, respiratory tract infections and subsequent hypoxic respiratory failure and ventilatory failure. The core mechanisms of how obesity causes this broad spectrum of respiratory complications include the addition of the physical load of adipose tissue onto the respiratory system and the systemic inflammatory state that it induces. Obesity has a close relationship with OSA and OHS; it is both causative and adds complexity to their disease progression and management. Weight loss is an important therapeutic strategy to ameliorate and resolve these deleterious effects. As the prevalence of obesity increases, a core understanding of its impact on the respiratory system will become increasingly relevant to all healthcare professionals.

Key points

  • The prevalence of obesity, and therefore obesity-related respiratory complications, is increasing and deserves close consideration by all healthcare professionals.

  • The effects of obesity on the respiratory system can be explained by the physical load that additional central adipose tissue has on the system, and a systemic inflammatory response that is induced with increased BMI.

  • Obesity causes reduced lung volumes and airway calibre, and increased airway hyperresponsiveness.

  • Obesity is a risk factor for, and exacerbates, respiratory tract infections, pulmonary vascular disease and ventilatory failure.

  • Weight loss is a key treatment modality for improving respiratory function in patients with raised BMI.

Self-evaluation questions

  1. A decrease in which of the following parameters is an early sign of respiratory compromise due to obesity?

    1. Total lung capacity

    2. Respiratory muscle strength

    3. Forced vital capacity

    4. Expiratory reserve volume

  2. Which of the following biomarkers tends to be reduced in obese individuals?

    1. Cytokines

    2. Leptin

    3. Adiponectin

    4. Tumour necrosis factor-α

  3. Obesity is an independent risk factor for which of the following conditions? Select all that apply.

    1. Lung cancer

    2. Pulmonary embolism

    3. Idiopathic pulmonary fibrosis

    4. Acute respiratory distress syndrome

  4. In obese patients suffering from ventilatory failure, neural respiratory drive is:

    1. Increased

    2. Decreased

    3. Unchanged

Suggested answers

1. d.

2. c.

3. b and d.

4. b.

Footnotes

  • Conflict of interest: N.M. Shah has nothing to disclose.

  • Conflict of interest: G. Kaltsakas has nothing to disclose.

  • Received November 17, 2022.
  • Accepted January 5, 2023.
  • Copyright ©ERS 2023
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Haslam D
    . Obesity: a medical history. Obes Rev 2007; 8: Suppl. 1, 31–36. doi:10.1111/j.1467-789X.2007.00314.x
    OpenUrlCrossRefPubMed
  2. ↵
    1. Eknoyan G
    . A history of obesity, or how what was good became ugly and then bad. Adv Chronic Kidney Dis 2006; 13: 421–427. doi:10.1053/j.ackd.2006.07.002
    OpenUrlCrossRefPubMed
  3. ↵
    1. National Institutes of Health
    . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. Obes Res 1998; 6: Suppl. 2, 51s–209s. doi:10.1002/j.1550-8528.1998.tb00690.x
    OpenUrl
  4. ↵
    1. Ansari S,
    2. Haboubi H,
    3. Haboubi N
    . Adult obesity complications: challenges and clinical impact. Ther Adv Endocrinol Metab 2020; 11: 2042018820934955. doi:10.1177/2042018820934955
    OpenUrl
  5. ↵
    1. Shah NM,
    2. Shrimanker S,
    3. Kaltsakas G
    . Defining obesity hypoventilation syndrome. Breathe (Sheff) 2021; 17: 210089. doi:10.1183/20734735.0089-2021
    OpenUrl
  6. ↵
    1. Collins LC,
    2. Hoberty PD,
    3. Walker JF, et al.
    The effect of body fat distribution on pulmonary function tests. Chest 1995; 107: 1298–1302. doi:10.1378/chest.107.5.1298
    OpenUrlCrossRefPubMed
  7. ↵
    1. NCD Risk Factor Collaboration (NCD-RisC)
    . Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 2016; 387: 1377–1396. doi:10.1016/S0140-6736(16)30054-X
    OpenUrlCrossRefPubMed
  8. ↵
    1. Katzmarzyk PT,
    2. Mason C
    . Prevalence of class I, II and III obesity in Canada. Can Med Assoc J 2006; 174: 156. doi:10.1503/cmaj.050806
    OpenUrlFREE Full Text
  9. ↵
    1. Keating C,
    2. Backholer K,
    3. Gearon E, et al.
    Prevalence of class-I, class-II and class-III obesity in Australian adults between 1995 and 2011–12. Obes Res Clin Pract 2015; 9: 553–562. doi:10.1016/j.orcp.2015.02.004
    OpenUrlCrossRefPubMed
  10. ↵
    1. Pelosi P,
    2. Luecke T,
    3. Rocco PR
    . Chest wall mechanics and abdominal pressure during general anaesthesia in normal and obese individuals and in acute lung injury. Curr Opin Crit Care 2011; 17: 72–79. doi:10.1097/MCC.0b013e3283427213
    OpenUrlCrossRefPubMed
    1. Naimark A,
    2. Cherniack RM
    . Compliance of the respiratory system and its components in health and obesity. J Appl Physiol 1960; 15: 377–382. doi:10.1152/jappl.1960.15.3.377
    OpenUrlPubMed
  11. ↵
    1. Brazzale DJ,
    2. Pretto JJ,
    3. Schachter LM
    . Optimizing respiratory function assessments to elucidate the impact of obesity on respiratory health. Respirology 2015; 20: 715–721. doi:10.1111/resp.12563
    OpenUrlPubMed
  12. ↵
    1. Lupi-Herrera E,
    2. Seoane M,
    3. Sandoval J, et al.
    Behavior of the pulmonary circulation in the grossly obese patient. Pathogenesis of pulmonary arterial hypertension at an altitude of 2,240 meters. Chest 1980; 78: 553–558. doi:10.1378/chest.78.4.553
    OpenUrlCrossRefPubMed
  13. ↵
    1. Salome CM,
    2. King GG,
    3. Berend N
    . Physiology of obesity and effects on lung function. J Appl Physiol (1985) 2010; 108: 206–211. doi:10.1152/japplphysiol.00694.2009
    OpenUrlCrossRefPubMed
  14. ↵
    1. Mafort TT,
    2. Rufino R,
    3. Costa CH, et al.
    Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med 2016; 11: 28. doi:10.1186/s40248-016-0066-z
    OpenUrlPubMed
  15. ↵
    1. Jones RL,
    2. Nzekwu M-MU
    . The effects of body mass index on lung volumes. Chest 2006; 130: 827–833. doi:10.1378/chest.130.3.827
    OpenUrlCrossRefPubMed
  16. ↵
    1. Littleton SW,
    2. Tulaimat A
    . The effects of obesity on lung volumes and oxygenation. Respir Med 2017; 124: 15–20. doi:10.1016/j.rmed.2017.01.004
    OpenUrl
  17. ↵
    1. Zerah F,
    2. Harf A,
    3. Perlemuter L, et al.
    Effects of obesity on respiratory resistance. Chest 1993; 103: 1470–1476. doi:10.1378/chest.103.5.1470
    OpenUrlCrossRefPubMed
  18. ↵
    1. Babb TG,
    2. Wyrick BL,
    3. DeLorey DS, et al.
    Fat distribution and end-expiratory lung volume in lean and obese men and women. Chest 2008; 134: 704–711. doi:10.1378/chest.07-1728
    OpenUrlCrossRefPubMed
  19. ↵
    1. Chlif M,
    2. Keochkerian D,
    3. Choquet D, et al.
    Effects of obesity on breathing pattern, ventilatory neural drive and mechanics. Respir Physiol Neurobiol 2009; 168: 198–202. doi:10.1016/j.resp.2009.06.012
    OpenUrlCrossRefPubMed
    1. Magnani KL,
    2. Cataneo AJ
    . Respiratory muscle strength in obese individuals and influence of upper-body fat distribution. Sao Paulo Med J 2007; 125: 215–219. doi:10.1590/S1516-31802007000400004
    OpenUrlCrossRefPubMed
    1. Kelly TM,
    2. Jensen RL,
    3. Elliott CG, et al.
    Maximum respiratory pressures in morbidly obese subjects. Respiration 1988; 54: 73–77. doi:10.1159/000195504
    OpenUrlPubMed
  20. ↵
    1. Steier J,
    2. Jolley CJ,
    3. Seymour J, et al.
    Neural respiratory drive in obesity. Thorax 2009; 64: 719–725. doi:10.1136/thx.2008.109728
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Sharp JT,
    2. Druz WS,
    3. Kondragunta VR
    . Diaphragmatic responses to body position changes in obese patients with obstructive sleep apnea. Am Rev Respir Dis 1986; 133: 32–37. doi:10.1164/arrd.1986.133.1.32
    OpenUrlPubMed
  22. ↵
    1. Sonpeayung R,
    2. Tantisuwat A,
    3. Janwantanakul P, et al.
    Total and compartmental chest wall volumes, lung function, and respiratory muscle strength in individuals with abdominal obesity: effects of body positions. J Obes 2019; 2019: 9539846. doi:10.1155/2019/9539846
    OpenUrl
  23. ↵
    1. Ray CS,
    2. Sue DY,
    3. Bray G, et al.
    Effects of obesity on respiratory function. Am Rev Respir Dis 1983; 128: 501–506. doi:10.1164/arrd.1983.128.3.501
    OpenUrlPubMed
    1. Costa D,
    2. Barbalho MC,
    3. Miguel GP, et al.
    The impact of obesity on pulmonary function in adult women. Clinics (Sao Paulo) 2008; 63: 719–724. doi:10.1590/S1807-59322008000600002
    OpenUrl
  24. ↵
    1. Ladosky W,
    2. Botelho MAM,
    3. Albuquerque JP
    . Chest mechanics in morbidly obese non-hypoventilated patients. Respir Med 2001; 95: 281–286. doi:10.1053/rmed.2001.1035
    OpenUrlCrossRefPubMed
  25. ↵
    1. Weiner P,
    2. Waizman J,
    3. Weiner M, et al.
    Influence of excessive weight loss after gastroplasty for morbid obesity on respiratory muscle performance. Thorax 1998; 53: 39–42. doi:10.1136/thx.53.1.39
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Farkas GA,
    2. Gosselin LE,
    3. Zhan WZ, et al.
    Histochemical and mechanical properties of diaphragm muscle in morbidly obese Zucker rats. J Appl Physiol (1985) 1994; 77: 2250–2259. doi:10.1152/jappl.1994.77.5.2250
    OpenUrlPubMed
  27. ↵
    1. Rodrigues GC,
    2. Rocha NN,
    3. LdA M, et al.
    Impact of experimental obesity on diaphragm structure, function, and bioenergetics. J Appl Physiol (1985) 2020; 129: 1062–1074. doi:10.1152/japplphysiol.00262.2020
    OpenUrl
  28. ↵
    1. Powers SK,
    2. Farkas GA,
    3. Demirel H, et al.
    Effects of aging and obesity on respiratory muscle phenotype in Zucker rats. J Appl Physiol (1985) 1996; 81: 1347–1354. doi:10.1152/jappl.1996.81.3.1347
    OpenUrlPubMed
  29. ↵
    1. Ekström MP,
    2. Blomberg A,
    3. Bergström G, et al.
    The association of body mass index, weight gain and central obesity with activity-related breathlessness: the Swedish Cardiopulmonary Bioimage Study. Thorax 2019; 74: 958–964. doi:10.1136/thoraxjnl-2019-213349
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Currow DC,
    2. Dal Grande E,
    3. Sidhu C, et al.
    The independent association of overweight and obesity with breathlessness in adults: a cross-sectional, population-based study. Eur Respir J 2017; 50: 1700558. doi:10.1183/13993003.00558-2017
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Sahebjami H
    . Dyspnea in obese healthy men. Chest 1998; 114: 1373–1377. doi:10.1378/chest.114.5.1373
    OpenUrlCrossRefPubMed
  32. ↵
    1. Sahebjami H,
    2. Gartside PS
    . Pulmonary function in obese subjects with a normal FEV1/FVC ratio. Chest 1996; 110: 1425–1429. doi:10.1378/chest.110.6.1425
    OpenUrlCrossRefPubMed
  33. ↵
    1. Bernhardt V,
    2. Moran RB,
    3. Bassett JT, et al.
    Breathlessness, but not oxygen cost of breathing, is higher during voluntary hyperpnea in obese women with vs without dyspnea on exertion. Am J Respir Crit Care Med 2014; 189: A5038.
    OpenUrl
  34. ↵
    1. Bernhardt V,
    2. Babb TG
    . Exertional dyspnoea in obesity. Eur Respir Rev 2016; 25: 487–495. doi:10.1183/16000617.0081-2016
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Sideleva O,
    2. Black K,
    3. Dixon AE
    . Effects of obesity and weight loss on airway physiology and inflammation in asthma. Pulm Pharmacol Ther 2013; 26: 455–458. doi:10.1016/j.pupt.2012.05.002
    OpenUrlCrossRefPubMed
  36. ↵
    1. Yap JC,
    2. Watson RA,
    3. Gilbey S, et al.
    Effects of posture on respiratory mechanics in obesity. J Appl Physiol (1985) 1995; 79: 1199–1205. doi:10.1152/jappl.1995.79.4.1199
    OpenUrlPubMed
  37. ↵
    1. Watson RA,
    2. Pride NB
    . Postural changes in lung volumes and respiratory resistance in subjects with obesity. J Appl Physiol (1985) 2005; 98: 512–517. doi:10.1152/japplphysiol.00430.2004
    OpenUrlCrossRefPubMed
  38. ↵
    1. Mahadev S,
    2. Salome CM,
    3. Berend N, et al.
    The effect of low lung volume on airway function in obesity. Respir Physiol Neurobiol 2013; 188: 192–199. doi:10.1016/j.resp.2013.05.021
    OpenUrlCrossRefPubMed
  39. ↵
    1. Pankow W,
    2. Podszus T,
    3. Gutheil T, et al.
    Expiratory flow limitation and intrinsic positive end-expiratory pressure in obesity. J Appl Physiol (1985) 1998; 85: 1236–1243. doi:10.1152/jappl.1998.85.4.1236
    OpenUrlPubMed
  40. ↵
    1. King GG,
    2. Brown NJ,
    3. Diba C, et al.
    The effects of body weight on airway calibre. Eur Respir J 2005; 25: 896–901. doi:10.1183/09031936.05.00104504
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Wilson AG,
    2. Massarella GR,
    3. Pride NB
    . Elastic properties of airways in human lungs post mortem. Am Rev Respir Dis 1974; 110: 716–729. doi:10.1164/arrd.1974.110.6P1.716
    OpenUrlPubMed
  42. ↵
    1. Shore SA,
    2. Fredberg JJ
    . Obesity, smooth muscle, and airway hyperresponsiveness. J Allergy Clin Immunol 2005; 115: 925–927. doi:10.1016/j.jaci.2005.01.064
    OpenUrlCrossRefPubMed
  43. ↵
    1. Ellulu MS,
    2. Patimah I,
    3. Khaza'ai H, et al.
    Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017; 13: 851–863. doi:10.5114/aoms.2016.58928
    OpenUrlCrossRefPubMed
  44. ↵
    1. Khafagy R,
    2. Dash S
    . Obesity and cardiovascular disease: the emerging role of inflammation. Front Cardiovasc Med 2021; 8: 768119. doi:10.3389/fcvm.2021.768119
    OpenUrl
  45. ↵
    1. Rohm TV,
    2. Meier DT,
    3. Olefsky JM, et al.
    Inflammation in obesity, diabetes, and related disorders. Immunity 2022; 55: 31–55. doi:10.1016/j.immuni.2021.12.013
    OpenUrlCrossRef
  46. ↵
    1. Deng T,
    2. Lyon CJ,
    3. Bergin S, et al.
    Obesity, Inflammation, and Cancer. Annu Rev Pathol 2016; 11: 421–449. doi:10.1146/annurev-pathol-012615-044359
    OpenUrlCrossRefPubMed
  47. ↵
    1. Dogan M,
    2. Han YS,
    3. Delmotte P, et al.
    TNFα enhances force generation in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2017; 312: L994–L1002. doi:10.1152/ajplung.00550.2016
    OpenUrlCrossRefPubMed
  48. ↵
    1. Polotsky M,
    2. Elsayed-Ahmed AS,
    3. Pichard L, et al.
    Effects of leptin and obesity on the upper airway function. J Appl Physiol (1985) 2012; 112: 1637–1643. doi:10.1152/japplphysiol.01222.2011
    OpenUrlCrossRefPubMed
  49. ↵
    1. Achari AE,
    2. Jain SK
    . Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 2017; 18: 1321. doi:10.3390/ijms18061321
    OpenUrlCrossRefPubMed
  50. ↵
    1. Salvator H,
    2. Grassin-Delyle S,
    3. Brollo M, et al.
    Adiponectin inhibits the production of TNF-α, IL-6 and chemokines by human lung macrophages. Front Pharmacol 2021; 12: 718929. doi:10.3389/fphar.2021.718929
    OpenUrl
  51. ↵
    1. Dixon AE,
    2. Pratley RE,
    3. Forgione PM, et al.
    Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128: 508–515. doi:10.1016/j.jaci.2011.06.009
    OpenUrlCrossRef
  52. ↵
    1. Bates JHT
    . Physiological mechanisms of airway hyperresponsiveness in obese asthma. Am J Respir Cell Mol Biol. 2016; 54: 618–623. http://dx.doi.org/10.1165/rcmb.2016-0019PS.
    OpenUrl
  53. ↵
    1. Beuther DA,
    2. Sutherland ER
    . Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007; 175: 661–666. doi:10.1164/rccm.200611-1717OC
    OpenUrlCrossRefPubMed
  54. ↵
    1. Taylor B,
    2. Mannino D,
    3. Brown C, et al.
    Body mass index and asthma severity in the National Asthma Survey. Thorax 2008; 63: 14–20. doi:10.1136/thx.2007.082784
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Akinbami LJ,
    2. Fryar CD
    . Current asthma prevalence by weight status among adults: United States, 2001–2014. NCHS data brief, no 239. Hyattsville, National Center for Health Statistics, 2016.
  56. ↵
    1. Mosen DM,
    2. Schatz M,
    3. Magid DJ, et al.
    The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008; 122: 507–511. doi:10.1016/j.jaci.2008.06.024
    OpenUrlCrossRefPubMed
  57. ↵
    1. Boulet LP,
    2. Franssen E
    . Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007; 101: 2240–2247. doi:10.1016/j.rmed.2007.06.031
    OpenUrlCrossRefPubMed
  58. ↵
    1. Sutherland ER,
    2. Goleva E,
    3. Strand M, et al.
    Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178: 682–687. doi:10.1164/rccm.200801-076OC
    OpenUrlCrossRefPubMed
  59. ↵
    1. Fuller-Thomson E,
    2. Howden KEN,
    3. Fuller-Thomson LR, et al.
    A strong graded relationship between level of obesity and COPD: findings from a national population-based study of lifelong nonsmokers. J Obes 2018; 2018: 6149263. doi:10.1155/2018/6149263
    OpenUrl
  60. ↵
    1. Steuten LM,
    2. Creutzberg EC,
    3. Vrijhoef HJ, et al.
    COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006; 15: 84–91. doi:10.1016/j.pcrj.2005.09.001
    OpenUrlCrossRefPubMed
  61. ↵
    1. Schokker DF,
    2. Visscher TL,
    3. Nooyens AC, et al.
    Prevalence of overweight and obesity in the Netherlands. Obes Rev 2007; 8: 101–108. doi:10.1111/j.1467-789X.2006.00273.x
    OpenUrlCrossRefPubMed
  62. ↵
    1. Watson L,
    2. Vonk JM,
    3. Löfdahl CG, et al.
    Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 2006; 100: 746–753. doi:10.1016/j.rmed.2005.08.004
    OpenUrlCrossRefPubMed
  63. ↵
    1. Guo Y,
    2. Zhang T,
    3. Wang Z, et al.
    Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis. Medicine (Baltimore) 2016; 95: e4225. doi:10.1097/MD.0000000000004225
    OpenUrlCrossRefPubMed
  64. ↵
    1. Franssen FME,
    2. O'Donnell DE,
    3. Goossens GH, et al.
    Obesity and the lung: 5. Obesity and COPD. Thorax 2008; 63: 1110–1117. doi:10.1136/thx.2007.086827
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Frank RC,
    2. Min J,
    3. Abdelghany M, et al.
    Obesity is associated with pulmonary hypertension and modifies outcomes. J Am Heart Assoc 2020; 9: e014195. doi:10.1161/JAHA.119.014195
    OpenUrl
  66. ↵
    1. McCarthy BE,
    2. McClelland RL,
    3. Appleby DH, et al.
    BMI and treatment response in patients with pulmonary arterial hypertension: a meta-analysis. Chest 2022; 162: 436–447. doi:10.1016/j.chest.2022.02.041
    OpenUrl
  67. ↵
    1. Min J,
    2. Feng R,
    3. Badesch D, et al.
    Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR). Ann Am Thorac Soc 2020; 18: 229–237. doi:10.1513/AnnalsATS.202006-612OC
    OpenUrl
  68. ↵
    1. Weatherald J,
    2. Huertas A,
    3. Boucly A, et al.
    Association between BMI and obesity with survival in pulmonary arterial hypertension. Chest 2018; 154: 872–881. doi:10.1016/j.chest.2018.05.006
    OpenUrl
  69. ↵
    1. McLean LL,
    2. Pellino K,
    3. Brewis M, et al.
    The obesity paradox in pulmonary arterial hypertension: the Scottish perspective. ERJ Open Res 2019; 5: 00241-2019. doi:10.1183/23120541.00241-2019
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Mazimba S,
    2. Holland E,
    3. Nagarajan V, et al.
    Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry. Int J Obes (Lond) 2017; 41: 1164–1168. doi:10.1038/ijo.2017.45
    OpenUrl
  71. ↵
    1. Johnston RA,
    2. Suratt BT
    1. Antkowiak MC,
    2. Channick RN
    . Chapter 9 - Obesity and pulmonary hypertension. In: Johnston RA, Suratt BT, ed. Mechanisms and Manifestations of Obesity in Lung Disease. Cambridge, Academic Press, 2019; pp. 201–226.
  72. ↵
    1. Friedman SE,
    2. Andrus BW
    . Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms. J Obes 2012; 2012: 505274. doi:10.1155/2012/505274
    OpenUrlCrossRefPubMed
  73. ↵
    1. Summer R,
    2. Walsh K,
    3. Medoff BD
    . Obesity and pulmonary arterial hypertension: is adiponectin the molecular link between these conditions? Pulm Circ 2011; 1: 440–447. doi:10.4103/2045-8932.93542
    OpenUrlCrossRefPubMed
  74. ↵
    1. Movahed MR,
    2. Khoubyari R,
    3. Hashemzadeh M, et al.
    Obesity is strongly and independently associated with a higher prevalence of pulmonary embolism. Respir Investig 2019; 57: 376–379. doi:10.1016/j.resinv.2019.01.003
    OpenUrl
  75. ↵
    1. Stein PD,
    2. Beemath A,
    3. Olson RE
    . Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978–980. doi:10.1016/j.amjmed.2005.03.012
    OpenUrlCrossRefPubMed
    1. Goldhaber SZ,
    2. Savage DD,
    3. Garrison RJ, et al.
    Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74: 1023–1028. doi:10.1016/0002-9343(83)90805-7
    OpenUrlCrossRefPubMed
  76. ↵
    1. Steffen LM,
    2. Cushman M,
    3. Peacock JM, et al.
    Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost 2009; 7: 746–751. doi:10.1111/j.1538-7836.2009.03295.x
    OpenUrlCrossRefPubMed
  77. ↵
    1. Eichinger S,
    2. Hron G,
    3. Bialonczyk C, et al.
    Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678–1683. doi:10.1001/archinte.168.15.1678
    OpenUrlCrossRefPubMed
  78. ↵
    1. Kabrhel C,
    2. Varraso R,
    3. Goldhaber SZ, et al.
    Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring) 2009; 17: 2040–2046. doi:10.1038/oby.2009.92
    OpenUrlCrossRefPubMed
  79. ↵
    1. Keller K,
    2. Hobohm L,
    3. Münzel T, et al.
    Survival benefit of obese patients with pulmonary embolism. Mayo Clin Proc 2019; 94: 1960–1973. doi:10.1016/j.mayocp.2019.04.035
    OpenUrl
  80. ↵
    1. Ho KS,
    2. Nasserifar S,
    3. Kohli P, et al.
    Dismantling the obesity paradox in acute pulmonary embolism. Eur Respir J 2020; 56: Suppl. 64, 3575. DOI:10.1183/13993003.congress-2020.3575
    OpenUrlCrossRef
  81. ↵
    1. Shah CD,
    2. Ramalingam V,
    3. Patel D D, et al.
    Obesity paradox in acute pulmonary embolism: fact or myth? Chest 2022; 162: Suppl. 4, A2433. doi:10.1016/j.chest.2022.08.1994
    OpenUrl
  82. ↵
    1. Mancuso P
    . Obesity and respiratory infections: does excess adiposity weigh down host defense? Pulm Pharmacol Ther 2013; 26: 412–419. doi:10.1016/j.pupt.2012.04.006
    OpenUrlCrossRefPubMed
  83. ↵
    1. Almond MH,
    2. Edwards MR,
    3. Barclay WS, et al.
    Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax 2013; 68: 684–686. doi:10.1136/thoraxjnl-2012-203009
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Vaillant L,
    2. La Ruche G,
    3. Tarantola A, et al.
    Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14: 19309. doi:10.2807/ese.14.33.19309-en
    OpenUrlCrossRefPubMed
    1. Gill JR,
    2. Sheng ZM,
    3. Ely SF, et al.
    Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010; 134: 235–243. doi:10.5858/134.2.235
    OpenUrlCrossRefPubMed
  85. ↵
    1. Jain S,
    2. Kamimoto L,
    3. Bramley AM, et al.
    Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935–1944. doi:10.1056/NEJMoa0906695
    OpenUrlCrossRefPubMed
  86. ↵
    1. Domínguez-Cherit G,
    2. Lapinsky SE,
    3. Macias AE, et al.
    Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302: 1880–1887. doi:10.1001/jama.2009.1536
    OpenUrlCrossRefPubMed
  87. ↵
    1. Sacco V,
    2. Rauch B,
    3. Gar C, et al.
    Overweight/obesity as the potentially most important lifestyle factor associated with signs of pneumonia in COVID-19. PLoS One 2020; 15: e0237799. doi:10.1371/journal.pone.0237799
    OpenUrl
  88. ↵
    1. Kwok S,
    2. Adam S,
    3. Ho JH, et al.
    Obesity: a critical risk factor in the COVID-19 pandemic. Clin Obes 2020; 10: e12403. doi:10.1111/cob.12403
    OpenUrl
  89. ↵
    1. Ni W,
    2. Yang X,
    3. Yang D, et al.
    Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020; 24: 422. doi:10.1186/s13054-020-03120-0
    OpenUrlCrossRefPubMed
  90. ↵
    1. Gammone MA,
    2. D'Orazio N
    . Review: obesity and COVID-19: a detrimental intersection. Front Endocrinol (Lausanne) 2021; 12: 652639. doi:10.3389/fendo.2021.652639
    OpenUrl
  91. ↵
    1. Behl T,
    2. Kumar S,
    3. Singh S, et al.
    Reviving the mutual impact of SARS-COV-2 and obesity on patients: from morbidity to mortality. Biomed Pharmacother 2022; 151: 113178. doi:10.1016/j.biopha.2022.113178
    OpenUrl
  92. ↵
    1. Maier HE,
    2. Lopez R,
    3. Sanchez N, et al.
    Obesity increases the duration of influenza A virus shedding in adults. J Infect Dis 2018; 218: 1378–1382. doi:10.1093/infdis/jiy370
    OpenUrlPubMed
  93. ↵
    1. Mojtabavi H,
    2. Saghazadeh A,
    3. Rezaei N
    . Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw 2020; 31: 44–49. doi:10.1684/ecn.2020.0448
    OpenUrlPubMed
  94. ↵
    1. Sindhu S,
    2. Thomas R,
    3. Shihab P, et al.
    Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation. PLoS One 2015; 10: e0133494. doi:10.1371/journal.pone.0133494
    OpenUrlCrossRefPubMed
  95. ↵
    1. Maurya R,
    2. Sebastian P,
    3. Namdeo M, et al.
    COVID-19 severity in obesity: leptin and inflammatory cytokine interplay in the link between high morbidity and mortality. Front Immunol 2021; 12: 649359. doi:10.3389/fimmu.2021.649359
    OpenUrl
  96. ↵
    1. Hojyo S,
    2. Uchida M,
    3. Tanaka K, et al.
    How COVID-19 induces cytokine storm with high mortality. Inflamm Regen 2020; 40: 37. doi:10.1186/s41232-020-00146-3
    OpenUrlPubMed
  97. ↵
    1. Clark A,
    2. Jit M,
    3. Warren-Gash C, et al.
    Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 2020; 8: e1003–e1017. doi:10.1016/S2214-109X(20)30264-3
    OpenUrl
  98. ↵
    1. Maccioni L,
    2. Weber S,
    3. Elgizouli M, et al.
    Obesity and risk of respiratory tract infections: results of an infection-diary based cohort study. BMC Public Health 2018; 18: 271. doi:10.1186/s12889-018-5172-8
    OpenUrlPubMed
  99. ↵
    1. Kornum JB,
    2. Nørgaard M,
    3. Dethlefsen C, et al.
    Obesity and risk of subsequent hospitalisation with pneumonia. Eur Respir J 2010; 36: 1330–1336. doi:10.1183/09031936.00184209
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Nie W,
    2. Zhang Y,
    3. Jee SH, et al.
    Obesity survival paradox in pneumonia: a meta-analysis. BMC Med 2014; 12: 61. doi:10.1186/1741-7015-12-61
    OpenUrlCrossRefPubMed
  101. ↵
    1. King P,
    2. Mortensen EM,
    3. Bollinger M, et al.
    Impact of obesity on outcomes for patients hospitalised with pneumonia. Eur Respir J 2013; 41: 929–934. doi:10.1183/09031936.00185211
    OpenUrlAbstract/FREE Full Text
  102. ↵
    1. Alsiö Å,
    2. Nasic S,
    3. Ljungström L, et al.
    Impact of obesity on outcome of severe bacterial infections. PLoS One 2021; 16: e0251887. doi:10.1371/journal.pone.0251887
    OpenUrl
  103. ↵
    1. Roth J,
    2. Sahota N,
    3. Patel P, et al.
    Obesity paradox, obesity orthodox, and the metabolic syndrome: an approach to unity. Mol Med 2017; 22: 873–885. doi:10.2119/molmed.2016.00211
    OpenUrl
  104. ↵
    1. Gong MN,
    2. Bajwa EK,
    3. Thompson BT, et al.
    Body mass index is associated with the development of acute respiratory distress syndrome. Thorax 2010; 65: 44–50. doi:10.1136/thx.2009.117572
    OpenUrlAbstract/FREE Full Text
  105. ↵
    1. Zhang W,
    2. Wang Y,
    3. Li W, et al.
    Association between obesity and short-and long-term mortality in patients with acute respiratory distress syndrome based on the Berlin definition. Front Endocrinol (Lausanne) 2020; 11: 611435. doi:10.3389/fendo.2020.611435
    OpenUrl
    1. Ni YN,
    2. Luo J,
    3. Yu H, et al.
    Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis. Crit Care 2017; 21: 36. doi:10.1186/s13054-017-1615-3
    OpenUrlCrossRef
  106. ↵
    1. Zhi G,
    2. Xin W,
    3. Ying W, et al.
    ‘Obesity paradox’ in acute respiratory distress syndrome: asystematic review and meta-analysis. PLoS One 2016; 11: e0163677. doi:10.1371/journal.pone.0163677
    OpenUrlCrossRefPubMed
  107. ↵
    1. Moxham J,
    2. Jolley C
    . Breathlessness, fatigue and the respiratory muscles. Clin Med (Lond) 2009; 9: 448–452. doi:10.7861/clinmedicine.9-5-448
    OpenUrl
  108. ↵
    1. Littleton SW
    . Impact of obesity on respiratory function. Respirology 2012; 17: 43–49. doi:10.1111/j.1440-1843.2011.02096.x
    OpenUrlCrossRefPubMed
  109. ↵
    1. Steier J,
    2. Lunt A,
    3. Hart N, et al.
    Observational study of the effect of obesity on lung volumes. Thorax 2014; 69: 752–759. doi:10.1136/thoraxjnl-2014-205148
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Onofri A,
    2. Patout M,
    3. Kaltsakas G, et al.
    Neural respiratory drive and cardiac function in patients with obesity hypoventilation syndrome following initiation of non-invasive ventilation. J Thorac Dis 2018; 10: Suppl. 1, S135–S143. doi:10.21037/jtd.2017.12.129
    OpenUrl
  111. ↵
    1. Sampson MG,
    2. Grassino AE
    . Load compensation in obese patients during quiet tidal breathing. J Appl Physiol Respir Environ Exerc Physiol 1983; 55: 1269–1276. doi:10.1152/jappl.1983.55.4.1269
    OpenUrlPubMed
  112. ↵
    1. Macavei VM,
    2. Spurling KJ,
    3. Loft J, et al.
    Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med 2013; 9: 879–884. doi:10.5664/jcsm.2986
    OpenUrlPubMed
  113. ↵
    1. Wolk R,
    2. Shamsuzzaman ASM,
    3. Somers VK, et al.
    Obesity, sleep apnea, and hypertension. Hypertension 2003; 42: 1067–1074. doi:10.1161/01.HYP.0000101686.98973.A3
    OpenUrlCrossRefPubMed
  114. ↵
    1. Romero-Corral A,
    2. Caples SM,
    3. Lopez-Jimenez F, et al.
    Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest 2010; 137: 711–719. doi:10.1378/chest.09-0360
    OpenUrlCrossRefPubMed
  115. ↵
    1. Peppard PE,
    2. Young T,
    3. Palta M, et al.
    Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284: 3015–3021. doi:10.1001/jama.284.23.3015
    OpenUrlCrossRefPubMed
  116. ↵
    1. Schwartz AR,
    2. Patil SP,
    3. Laffan AM, et al.
    Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc 2008; 5: 185–192. doi:10.1513/pats.200708-137MG
    OpenUrlCrossRefPubMed
  117. ↵
    1. Spiegel K,
    2. Tasali E,
    3. Penev P, et al.
    Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141: 846–850. doi:10.7326/0003-4819-141-11-200412070-00008
    OpenUrlCrossRefPubMed
  118. ↵
    1. Greer SM,
    2. Goldstein AN,
    3. Walker MP
    . The impact of sleep deprivation on food desire in the human brain. Nat Commun 2013; 4: 2259. doi:10.1038/ncomms3259
    OpenUrlCrossRefPubMed
  119. ↵
    1. Cowan DC,
    2. Livingston E
    . Obstructive sleep apnoea syndrome and weight loss: review. Sleep Disord 2012; 2012: 163296. doi:10.1155/2012/163296
    OpenUrl
  120. ↵
    1. Kuna ST,
    2. Reboussin DM,
    3. Strotmeyer ES, et al.
    Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med 2020; 203: 221–229. doi:10.1164/rccm.201912-2511OC
    OpenUrl
  121. ↵
    1. Murphy PB,
    2. Janssens JP
    . NIV for OHS without severe OSAS: is it worth it? Thorax 2016; 71: 877–878. doi:10.1136/thoraxjnl-2016-208986
    OpenUrlFREE Full Text
    1. Masa JF,
    2. Corral J,
    3. Caballero C, et al.
    Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax 2016; 71: 899–906. doi:10.1136/thoraxjnl-2016-208501
    OpenUrlAbstract/FREE Full Text
  122. ↵
    1. Egea-Santaolalla C,
    2. Javaheri S
    . Obesity hypoventilation syndrome. Curr Sleep Medicine Rep 2016; 2: 12–19. doi:10.1007/s40675-016-0035-2
    OpenUrl
  123. ↵
    1. Javaheri S,
    2. Colangelo G,
    3. Lacey W, et al.
    Chronic hypercapnia in obstructive sleep apnea-hypopnea syndrome. Sleep 1994; 17: 416–423. doi:10.1093/sleep/17.5.416
    OpenUrlPubMed
  124. ↵
    1. Javaheri S,
    2. Shore NS,
    3. Rose B, et al.
    Compensatory hypoventilation in metabolic alkalosis. Chest 1982; 81: 296–301. doi:10.1378/chest.81.3.296
    OpenUrlCrossRefPubMed
  125. ↵
    1. Thomas PS,
    2. Cowen ER,
    3. Hulands G, et al.
    Respiratory function in the morbidly obese before and after weight loss. Thorax 1989; 44: 382–386. doi:10.1136/thx.44.5.382
    OpenUrlAbstract/FREE Full Text
    1. Hakala K,
    2. Maasilta P,
    3. Sovijärvi AR
    . Upright body position and weight loss improve respiratory mechanics and daytime oxygenation in obese patients with obstructive sleep apnoea. Clin Physiol 2000; 20: 50–55. doi:10.1046/j.1365-2281.2000.00223.x
    OpenUrlCrossRefPubMed
  126. ↵
    1. Sugerman HJ,
    2. Fairman RP,
    3. Baron PL, et al.
    Gastric surgery for respiratory insufficiency of obesity. Chest 1986; 90: 81–86. doi:10.1378/chest.90.1.81
    OpenUrlCrossRefPubMed
    1. Emirgil C,
    2. Sobol BJ
    . The effects of weight reduction on pulmonary function and the sensitivity of the respiratory center in obesity. Am Rev Respir Dis 1973; 108: 831–842. doi:10.1164/arrd.1973.108.4.831
    OpenUrlPubMed
  127. ↵
    1. Vaughan RW,
    2. Cork RC,
    3. Hollander D
    . The effect of massive weight loss on arterial oxygenation and pulmonary function tests. Anesthesiology 1981; 54: 325–328. doi:10.1097/00000542-198104000-00013
    OpenUrlCrossRefPubMed
  128. ↵
    1. Wadström C,
    2. Müller-Suur R,
    3. Backman L
    . Influence of excessive weight loss on respiratory function. A study of obese patients following gastroplasty. Eur J Surg 1991; 157: 341–346.
    OpenUrlPubMed
    1. Aaron SD,
    2. Fergusson D,
    3. Dent R, et al.
    Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest 2004; 125: 2046–2052. doi:10.1378/chest.125.6.2046
    OpenUrlCrossRefPubMed
  129. ↵
    1. Womack CJ,
    2. Harris DL,
    3. Katzel LI, et al.
    Weight loss, not aerobic exercise, improves pulmonary function in older obese men. J Gerontol A Biol Sci Med Sci 2000; 55: M453–M457. doi:10.1093/gerona/55.8.M453
    OpenUrlCrossRefPubMed
  130. ↵
    1. Bhammar DM,
    2. Stickford JL,
    3. Bernhardt V, et al.
    Effect of weight loss on operational lung volumes and oxygen cost of breathing in obese women. Int J Obes (Lond) 2016; 40: 998–1004. doi:10.1038/ijo.2016.21
    OpenUrl
  131. ↵
    1. Dávila-Cervantes A,
    2. Domínguez-Cherit G,
    3. Borunda D, et al.
    Impact of surgically-induced weight loss on respiratory function: a prospective analysis. Obes Surg 2004; 14: 1389–1392. doi:10.1381/0960892042583996
    OpenUrlCrossRefPubMed
    1. Santana ANC,
    2. Souza R,
    3. Martins AP, et al.
    The effect of massive weight loss on pulmonary function of morbid obese patients. Respir Med 2006; 100: 1100–1104. doi:10.1016/j.rmed.2005.09.021
    OpenUrlCrossRefPubMed
  132. ↵
    1. Peralta GP,
    2. Marcon A,
    3. Carsin A-E, et al.
    Body mass index and weight change are associated with adult lung function trajectories: the prospective ECRHS study. Thorax 2020; 75: 313–320. doi:10.1136/thoraxjnl-2019-213880
    OpenUrlAbstract/FREE Full Text
  133. ↵
    1. Rochester DF,
    2. Enson Y
    . Current concepts in the pathogenesis of the obesity-hypoventilation syndrome: Mechanical and circulatory factors. Am J Med 1974; 57: 402–420. doi:10.1016/0002-9343(74)90135-1
    OpenUrlCrossRefPubMed
  134. ↵
    1. El-Gamal H,
    2. Khayat A,
    3. Shikora S, et al.
    Relationship of dyspnea to respiratory drive and pulmonary function tests in obese patients before and after weight loss. Chest 2005; 128: 3870–3874. doi:10.1378/chest.128.6.3870
    OpenUrlCrossRefPubMed
  135. ↵
    1. Zavorsky GS,
    2. Hoffman SL
    . Pulmonary gas exchange in the morbidly obese. Obes Rev 2008; 9: 326–339. doi:10.1111/j.1467-789X.2008.00471.x
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 19 Issue 1 Table of Contents
Breathe: 19 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Respiratory complications of obesity: from early changes to respiratory failure
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Respiratory complications of obesity: from early changes to respiratory failure
Neeraj M. Shah, Georgios Kaltsakas
Breathe Mar 2023, 19 (1) 220263; DOI: 10.1183/20734735.0263-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Respiratory complications of obesity: from early changes to respiratory failure
Neeraj M. Shah, Georgios Kaltsakas
Breathe Mar 2023, 19 (1) 220263; DOI: 10.1183/20734735.0263-2022
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Epidemiology
    • Pulmonary physiology
    • Airway limitation
    • Asthma and COPD
    • Pulmonary vascular disease
    • Respiratory tract infections and acute respiratory distress syndrome
    • Respiratory failure
    • OSA
    • OHS
    • Weight loss
    • Summary
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Management of difficult-to-treat asthma in adolescence and young adults
  • Diagnosis and management of PH in infants with BPD
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society